Celcuity Shares Surge After Exciting Phase 3 Trial Results

Celcuity shares are trading higher after the company announced clinically meaningful improvements in progression-free survival in its Phase 3 VIKTORIA-1 trial, showcasing the potential of gedatolisib as a breakthrough treatment for advanced breast cancer.